Tislelizumab Combination Improves Long-Term Survival in Extensive-Stage Small Cell Lung Cancer

First-line immunotherapy has significantly altered the treatment landscape for extensive-stage small cell lung cancer (ES-SCLC), but long-term survival data remain crucial in a disease characterized by rapid progression and historically poor outcomes. Recent long-term follow-up results from the phase 3 RATIONALE-312 trial provide further evidence supporting the utilize of tislelizumab plus chemotherapy in ES-SCLC, demonstrating that the initial survival advantage observed has been maintained with extended follow-up, while the safety profile remains consistent and manageable .

Why This Matters

Extensive-stage small cell lung cancer continues to be one of the most aggressive thoracic malignancies. While platinum-etoposide has long been the standard treatment, the addition of immune checkpoint inhibitors has grow the recent standard first-line approach, as demonstrated by phase 3 trials showing meaningful gains in overall survival. Clinicians closely examine long-term follow-up analyses to determine if early benefits translate into durable outcomes over time.

The updated RATIONALE-312 data are essential as the initial analysis showed that adding tislelizumab to chemotherapy improved both overall survival and progression-free survival compared to placebo plus chemotherapy. This long-term follow-up confirms that this benefit is not temporary and tislelizumab plus chemotherapy continues to display a clinically meaningful overall survival advantage, including encouraging landmark survival rates at three and four years .

RATIONALE-312 Trial Design

RATIONALE-312 was a randomized, double-blind, placebo-controlled phase 3 study conducted at 51 centers in China . Adults with histologically or cytologically confirmed ES-SCLC and no prior systemic therapy were enrolled if they had an ECOG performance status of 0 or 1. Patients were randomized 1:1 to receive four cycles of intravenous tislelizumab 200 mg or placebo every three weeks, combined with etoposide and either carboplatin or cisplatin. This was followed by maintenance tislelizumab or placebo every three weeks until disease progression, unacceptable toxicity, loss of clinical benefit, or withdrawal of consent .

The primary endpoint was overall survival. Key secondary endpoints included progression-free survival and safety. Exploratory analyses assessed outcomes according to PD-L1 expression .

A total of 457 patients were randomized, with 227 assigned to the tislelizumab arm and 230 to the placebo arm. Chemotherapy choice was carboplatin in 79.0% of patients and cisplatin in 21.0%. Baseline characteristics were generally well-balanced, although the tislelizumab group had a somewhat higher baseline tumor burden, with a greater proportion of stage IV disease, liver metastases, and three or more distant metastatic sites .

Study Population Characteristics

The study population reflected a typical first-line ES-SCLC cohort in China. The median age was 63.0 years in the tislelizumab arm and 62.0 years in the placebo arm. Men accounted for 81.9% and 80.9% of the two groups, respectively. Most patients had an ECOG performance status of 1, including 84.6% in the tislelizumab group and 85.2% in the placebo group. Stage IV disease was present in 91.2% and 87.4%, respectively .

Liver metastases were documented in 28.2% of patients receiving tislelizumab and 25.7% receiving placebo. Brain metastases were uncommon, occurring in only 0.4% and 1.7% of patients, respectively. Carboplatin was selected for approximately four out of five patients in both arms. Never-smokers represented 23.3% of the tislelizumab arm and 25.7% of the placebo arm, a proportion consistent with previously reported incidence in Asia and other phase 3 trials conducted in China .

Overall Survival Benefit

The most important finding from the long-term follow-up was the sustained overall survival benefit. With a median survival follow-up of 39.8 months in the tislelizumab arm and 36.4 months in the placebo arm, median overall survival reached 15.5 months with tislelizumab plus chemotherapy versus 13.5 months with placebo plus chemotherapy. This translated to a hazard ratio of 0.78 (95% CI, 0.63-0.95) .

This means the addition of tislelizumab reduced the risk of death by 22% relative to chemotherapy alone. The 3-year overall survival rate was 22.1% with tislelizumab plus chemotherapy compared with 13.1% in the placebo arm. At 4 years, the overall survival rate in the tislelizumab arm was 18.9%, and seven patients remained at risk, whereas no patients remained at risk in the placebo arm .

Progression-Free Survival

In addition to overall survival, progression-free survival favored the immunotherapy arm. Median progression-free survival was 4.7 months with tislelizumab plus chemotherapy versus 4.3 months with placebo plus chemotherapy, corresponding to a hazard ratio of 0.65 (95% CI, 0.53-0.80) .

Benefit Across PD-L1 Subgroups

Among PD-L1–evaluable patients, median overall survival was 20.7 months in the tislelizumab arm compared with 13.5 months in the placebo arm, with a hazard ratio of 0.71 (95% CI, 0.48-1.06) . The investigators reported that overall survival benefit favored tislelizumab across all PD-L1 subgroups.

Safety Profile

The long-term safety analysis did not reveal new concerns. Treatment-emergent adverse events occurred in 99.6% of patients in both groups. Grade 3 or higher treatment-emergent adverse events were seen in 89.0% of the tislelizumab arm and 90.0% of the placebo arm. Treatment-related adverse events leading to discontinuation of any treatment component were more frequent with tislelizumab at 13.2% compared with 3.1% in the placebo group .

Clinical Implications

These long-term follow-up data support tislelizumab plus chemotherapy as a durable first-line option for ES-SCLC. The regimen maintained its overall survival advantage with extended follow-up, improved progression-free survival, showed encouraging long-term landmark survival rates, and remained manageable from a safety perspective. Tislelizumab has already received approval in China and Europe for first-line treatment of ES-SCLC based on RATIONALE-312 .

The study population was entirely from centers in China, PD-L1 testing was retrospective and not mandatory, and the number of patients with brain metastases was small. These limitations should be considered when extrapolating the data.